Avanços nas anormalidades genéticas envolvidas na patogênese da leucemia mieloide aguda
DOI:
https://doi.org/10.31053/1853.0605.v76.n2.24329Palavras-chave:
leucemia mieloide aguda, sequenciamento, mutação, FLT3, NMP1Resumo
.Downloads
Referências
T. Boveri, Zur Frage der Entstehung maligner Tumoren, Fischer, Jena, 1914.
Goldman JM, Melo JV. Chronic myeloid leukemia--advances in biology and new approaches to treatment. N Engl J Med. 2003; 349(15):1451-64.
Golomb HM, Tests JR, Vardiman JW. Cytogenetic and ultrastructural features of de novo acute promyelocytic leukemia: The University of Chicago experience (1973-1978). Cancer Genetics and Cytogenetics. 1979; 1:69-78.
Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004;18(2):115-36.
Sanger F, Coulson AR. A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. J Mol Biol. 1975; 94: 441-8.
Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100: 59-66.
Shayegi N , Kramer M , Bornhauser M, et al. The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. Blood. 2013;122: 83-92.
Leisch M, Jansko B, Zaborsky N, Greil R, Pleyer L. Next Generation Sequencing in AML—On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?. Cancers (Basel). 2019;11(2). pii: E252
Ley TJ, Mardis ER, Ding Li, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature. 2008;456(7218):66-72.
Ilyas AM, Ahmad S, Faheem M1, et al. BMC Genomics. 2015;16(Suppl 1):S5-S12.
Davis JR, Benjamin DJ, Jonas BA. New and emerging therapies for acute
myeloid leukaemia. J Investig Med. 2018;66(8):1088-95.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2019 Universidad Nacional de Córdoba
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial 4.0 International License.
A geração de trabalhos derivados é permitida, desde que não seja feita para fins comerciais. O trabalho original não pode ser usado para fins comerciais.
Como Citar
